The Humira patent thicket, the Noerr-Pennington doctrine and antitrust's patent problem
Nat Biotechnol
.
2022 Dec;40(12):1761-1763.
doi: 10.1038/s41587-022-01583-w.
Authors
Ryan Knox
1
,
Gregory Curfman
2
Affiliations
1
Harvard-MIT Center for Regulatory Science, Boston, MA, USA.
2
JAMA, Chicago, IL, USA. gregory.curfman@jamanetwork.org.
PMID:
36477501
DOI:
10.1038/s41587-022-01583-w
No abstract available
MeSH terms
Adalimumab*
Substances
Adalimumab